Ginkgo Bioworks Holdings Inc. Class A Common Stock (DNA)
Stock · NYSE · Health Care
$10.28as of 10/16/2026
Price chart
Active signals
DNA Signal Track Record
How signals performed across all stocks →What DNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -4.0% | 42% | October 5, 2026 |
| Bollinger Band Breakout | 22 | -12.4% | 27% | October 5, 2026 |
| Bollinger Band Breakdown | 16 | -9.3% | 38% | July 17, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +0.3% | 56% | July 7, 2026 |
| Any 20-session window (baseline) | -3.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence mode…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 485
Fundamentals
- 1-day range
- $10.4$11.8
- Market cap
- $528.15M
- P/E (trailing)
- —
- P/E (forward)
- -4.06
- EPS (trailing)
- $-5.00
- Dividend yield
- —
- Beta
- 1.69
- Avg. volume
- 1.92M
How Ginkgo Bioworks Holdings Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Ginkgo Bioworks Holdings Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapybenzinga · 10/9/2026
- Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye TherapyBenzinga · 10/9/2026
- What's Going on With Ginkgo Bioworks Stock on Friday?Benzinga · 10/9/2026
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- Ginkgo Bioworks To Provide Autonomous Lab Access To NSF X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5B Science Program; To Provide Cloud Lab Time And Remote Access For NSF X-Labs Teams; To Offer Protein Testing Services To NSF X-Labs TeamsBenzinga · 10/8/2026
- Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-LoopYahoo · 10/8/2026
- Ginkgo Bioworks To Integrate Araceli Biosciences' Endeavor High-Content Imaging Instrument Into Nebula, The Company's Autonomous LabBenzinga · 10/8/2026
- Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to KnowYahoo · 10/7/2026
- Ginkgo Bioworks: The Valuation Has Outrun The BusinessSeekingAlpha · 10/7/2026
Insider Activity
Insider Actions →- Coen Steven P. · October 5, 2026 · Sale2.4K @ $15
- Christian O. Henry · September 15, 2026 · Sale5.0K @ $7.08
- Coen Steven P. · August 24, 2026 · Sale330 @ $6.98
- Coen Steven P. · August 21, 2026 · Option Exercise156
- Coen Steven P. · August 21, 2026 · Option Exercise587
- Canton Barry · July 28, 2026 · Grant127.4K
- Canton Barry · July 28, 2026 · Grant39.0K
- Canton Barry · July 28, 2026 · Grant117.1K
- Canton Barry · July 28, 2026 · Grant35.7K
- Shetty Reshma P. · July 28, 2026 · Grant117.1K
- Shetty Reshma P. · July 28, 2026 · Grant35.7K
- Shetty Reshma P. · July 28, 2026 · Grant127.4K
- Shetty Reshma P. · July 28, 2026 · Grant39.0K
- Kelly Jason R · July 28, 2026 · Grant309.5K
- Kelly Jason R · July 28, 2026 · Grant74.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 30.70M
- Total value held
- $185.43M
- Institutional holders
- 165
- Unknown3.64M
- Unknown3.58M
- Unknown2.39M
- Unknown1.95M
- Unknown1.91M
- Unknown1.75M
- Unknown1.66M
- Unknown1.35M
- Unknown1.01M
- Unknown929.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value
Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value. Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.